GTN (Biotechnology, Quantum) — Funding, Investors & Signals 2026

GTN

Developing a new drug costs $2.9bn, GTN uses technology to halve development costs and discover new molecules.

Founded 2017

London, United Kingdom 2-10 employees Seed Total: $2.10M Biotechnology, Quantum +1

GTN: GTN is a biotechnology startup based in the United Kingdom, founded in 2017. The company is focused on revolutionizing drug discovery by leveraging its innovative Generative Tensorial Networks technology. GTN's mission is articulated in its slogan: "Developing a new drug costs $2.9bn, GTN uses technology to halve development costs and discover new molecules." GTN addresses the daunting cost and diminishing productivity of drug development, as it currently averages $2.9 billion for bringing a single novel drug to the market. The company's approach is to utilize a unique blend of machine learning and quantum physics methodologies to simulate, filter, and explore the vast realm of drug-like molecules. This method enables the discovery of previously unknown compounds while significantly reducing development expenses. In 2018, GTN secured a Seed Round investment from Entrepreneur First and Isomer Capital, indicating the support and confidence of established investors in the company's vision and technology. This investment empowers GTN to continue its groundbreaking work in the intersection of biotechnology, quantum, and machine learning.

Funding Stage	Amount	Investors	Lead Investors	Date
Seed Round	••••••	2		01 Nov 2018
Seed Round	••••••	3		04 May 2018
Non Equity Assistance	••••••	1	•••• ••••	01 Jun 2017

Funding Stage

Amount

Investors

Lead Investors

Date

Seed Round

••••••

01 Nov 2018

Seed Round

••••••

04 May 2018

Non Equity Assistance

••••••

•••• ••••

01 Jun 2017

FAQ About GTN

Developing a new drug costs $2.9bn, GTN uses technology to halve development costs and discover new molecules.

GTN was founded in 2017.

GTN is headquartered in London, United Kingdom.

GTN operates in the following industries: Biotechnology, Quantum, Machine Learning.

GTN has approximately 2-10 employees.

GTN has completed 3 funding rounds, raising a total of $2.10M. The latest funding stage is Seed.

GTN offers: Domain sales, AI technology.

Top alternatives and competitors to GTN include Nanoform, OrganoTherapeutics, NewBiotics, Pledge Therapeutics, AnnJi Pharmaceutical Co., Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

GTN and Nanoform are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

GTN

General Information

Track GTN

Discover More

About GTN

Services & Products

Target Customers

Funding Rounds & Investors (3)

GTN Alternatives & Competitors

FAQ About GTN

Don't just browse. Track.